At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AGIO Agios Pharmaceuticals
Pre-Market Trading 12-23 07:46:15 EST
35.42
-0.39
-1.09%
盘前35.75
+0.33+0.93%
07:41 EST
High36.30
Low35.13
Vol3.20M
Open35.50
D1 Closing35.81
Amplitude3.27%
Mkt Cap2.02B
Tradable Cap1.79B
Total Shares57.03M
T/O113.49M
T/O Rate6.33%
Tradable Shares50.52M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Agios Pharmaceuticals Says Mitapivat Granted EU Orphan Drug Status for Sickle Cell Disease
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.